Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
ILA
vs
S
S&P/ASX 300
ILA
Over the past 12 months, ILA has underperformed S&P/ASX 300, delivering a return of -5% compared to S&P/ASX 300's 4% drop.
Stocks Performance
ILA vs S&P/ASX 300
Performance Gap
ILA vs S&P/ASX 300
Performance By Year
ILA vs S&P/ASX 300
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Island Pharmaceuticals Ltd
Glance View
Island Pharmaceuticals is a drug-development company that focuses on medicines for viral diseases, especially mosquito-borne infections such as dengue and other flaviviruses. It does not sell a broad line of commercial drugs; instead, it works to identify existing compounds that can be repurposed or advanced into new treatments. Its main customers, in the long run, would be hospitals, doctors, governments, and drug distributors if any of its candidates reach market approval. The company makes money mainly as a development-stage biotech: it depends on research funding and capital raising today, and it would look to earn licensing income, partnership payments, or product sales later if a drug candidate succeeds. That makes its business different from a traditional drugmaker. The value is tied less to current sales and more to whether its research can turn into a viable antiviral medicine. Its role in the industry is that of an early pipeline builder, not a mass manufacturer or pharmacy brand. It takes on the scientific and regulatory work needed to move a drug candidate toward testing and approval, then often partners with larger drug companies or healthcare buyers to commercialize it. In plain terms, Island is trying to turn lab-stage antiviral ideas into treatments that bigger players can distribute and sell.